Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities

WEST LAFAYETTE, Ind., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading Contract Research Organization (CRO) specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, and VUGENE, a multi-omics data analysis company providing advanced artificial intelligence (AI) and machine learning (ML) solutions for biomedical research, today announced a strategic collaboration designed to accelerate AI-assisted drug discovery and enhance data-driven insights across the drug development continuum.

Through this partnership, Inotiv will integrate VUGENE's cloud-based bioinformatics and computational platform into its Discovery & Translational Sciences Division, enabling a more efficient and intelligent analysis of complex biological data. The collaboration will enhance Inotiv's ability to interpret the full spectrum of epigenomic, proteomic, and other molecular datasets, with the goal of ultimately improving the prediction of drug efficacy and safety in early-stage research.

"To maximize the value of our clients' discovery programs, we must efficiently integrate and interpret complex datasets," said Scott Daniels, PhD, Senior Vice President of Drug Discovery & Translational Sciences at Inotiv. "VUGENE's AI-enabled bioinformatics platform gives our team a powerful tool to advance data-driven, AI-assisted discovery, helping clients make faster, more informed decisions."

For VUGENE, the partnership is an opportunity to expand the reach and application of its computational technologies within real-world research environments.

"Inotiv's integrated approach to drug discovery, specifically their focus on the qualification of new target biology and disease modeling, makes them an ideal partner," said Juozas Gordevičius, PhD, Founder and CTO of VUGENE. "Together we can combine advanced multi-omics bioinformatics and AI with experimental expertise to accelerate scientific breakthroughs and improve human health."

About Inotiv

Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company's products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs and medical devices to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical research and development projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotiv.com/.

About VUGENE

VUGENE is a global multi-omics data analysis and interpretation company. The VUGENE platform enables the elucidation of disease mechanisms and therapeutic mode-of-action, assisting in the discovery and development of novel treatments. The VUGENE platform integrates biological data from multiple sources including tissue and cellular sources and range from (epi)genomics, transcriptomics, proteomics and metabolomics.

This release contains "forward-looking statements," within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identified with words such as "aim", "anticipate", "assume", "believe", "could", "estimate", "expect", "future", "goal", "intend", "likely", "may", "plan", "project", "seek", "strategy", "target", "will" and similar expressions. Forward-looking statements in this release include, but are not limited to, statements regarding the Company's new strategic collaboration, including the workings of the collaboration and its expected effects, impacts and results, potential expansions and additional innovation, and commitments to new approach methodologies and their expected effects, impacts and results. These forward-looking statements are not statements of historical facts and represent only the Company's current expectations regarding such matters. All forward-looking statements are subject to significant risks, uncertainties and changes in circumstances that could cause actual results and outcomes to differ materially from those expressed or implied in the forward-looking statements, including, but are not limited to, those detailed in the Company's filings with the U.S. Securities and Exchange Commission. Further discussion of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in the Company's Annual Report on Form 10-K as filed on December 4, 2024, as well as other filings with the Securities and Exchange Commission. Except to the extent required by law, the Company does not undertake, and expressly disclaims, any duty or obligation to update publicly any forward-looking statement after the date of this release, whether as a result of new information, future events, changes in assumptions or otherwise.